114 results on '"Shiffman M"'
Search Results
2. 223: Development of a CF primary palliative care intervention: Perceptions and preferences of individuals with CF and family caregivers
3. 219: Improving assessment for CF pediatric palliative care: Initial development of the ADAPT-CF communication guide with children and caregivers
4. P254 Development of a primary palliative care model that includes a novel approach to address the needs of caregivers of adults with cystic fibrosis - improving life with cystic fibrosis: a primary palliative care partnership
5. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
6. Outcomes of liver transplantation patients with end stage liver disease receiving their pre- and post-transplant care locally versus perioperative care at the liver transplant center
7. Sustained and continued improvement in hepatic fibrosis beyond the first year following hepatitis C virus treatment
8. Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC)
9. Pharmacokinetics and pharmacodynamics of seladelpar, a potent and selective PPAR-delta, in patients with primary biliary cholangitis
10. Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study
11. Change in bilirubin with obeticholic acid treatment in primary biliary cholangitis patients with high baseline bilirubin: a retrospective analysis of POISE, 201, and 202
12. A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy
13. Durable response in the markers of cholestasis through 36 months of open-label extension study of obeticholic acid in primary biliary cholangitis
14. Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
15. Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis
16. Serum fibroblast growth factor 19, 7α-Hydroxy-4-Cholesten-3-one, and bile acids and their associations with clinical characteristics in primary sclerosing cholangitis
17. Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C in patients aged 65 years or older: a retrospective analysis of phase 3 studies
18. Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis
19. Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis
20. Durable response in the markers of cholestasis through 18 months of open-label extension with obeticholic acid in primary biliary cholangitis
21. Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis
22. Emricasan (IDN-6556) Orally for Three Months in Patients with Cirrhosis and Meld Scores 11–18 Improves Clinical Parameters of Cirrhosis in Patients with Baseline Meld Score ≥ 15
23. LP37 : A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases
24. Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin
25. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin
26. 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
27. 1151 CONTINUED HIGH VIROLOGIC RESPONSE RATES WITH ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A IN A 28-DAY AND 12-WEEK PHASE 2A TRIAL
28. 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS
29. 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
30. 478 INFECTIONS DURING PEGINTERFERON (PEGIFN)/RIBAVIRIN (RBV) THERAPY ARE ASSOCIATED WITH THE MAGNITUDE OF DECLINE IN THE LYMPHOCYTE COUNT: RESULTS OF THE IDEAL STUDY
31. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
32. 287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT
33. 1174 ASSOCIATION OF IL28B GENOTYPE WITH VIROLOGICAL RESPONSE TO PEGYLATED-INTERFERON PLUS RIBAVIRIN IN PATIENTS WITH ADVANCED CHRONIC HEPATITIS C ENROLLED IN THE HALT-C TRIAL
34. 765 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RESPONSE (RPCDBDR) TRIAL OF CTS-1027, AN INHIBITOR OF MATRIX METALLOPROTEASES (MMPS) IN PATIENTS WITH HCV WHO HAD FAILED PRIOR THERAPIES
35. 2015 GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A CAUSAL ROLE FOR ITPA GENETIC VARIATION IN RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA
36. Clinical trial: efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C
37. 1049 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 PATIENTS: INTERIM ANALYSIS SHOWS INCREASE IN EVR
38. 643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION
39. 1059 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF NITAZOXANIDE WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN NONRESPONDERS (NR) WITH CHRONIC HCV GENOTYPE 1: WEEK 28 INTERIM ANALYSIS
40. 14 EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C
41. 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY
42. 128 FIVE YEAR PROSPECTIVE EVALUATION OF LIVER HISTOLOGY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) FOLLOWING TREATMENT WITH INTERFERON/PEGINTERFERON AND RIBAVIRIN (IFNTX)
43. 628 RANDOMIZED TRIAL COMPARING SYSTEMIC AND LOCAL REACTIONS TO CONTROLLED-RELEASE INTERFERON ALPHA2B AND PEGYLATED-INTERFERON ALPHA2B IN HEPATITIS C PATIENTS WHO FAILED PRIOR TREATMENT
44. 596 SUSTAINED VIROLOGICAL RESPONSE RATES IN PATIENTS ACHIEVING SLOW RESPONSE OR COMPLETE EARLY VIROLOGICAL RESPONSE (CEVR) WITH CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE DIRECT TRIAL
45. BILIARY COMPLICATIONS IN ADULT TO ADULT LIVING DONOR RIGHT LOBE LIVER TRANSPLANTS - LONG TERM RESULTS
46. Histological benefits of virological response to peginterferon alfa‐2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis
47. 1000 A STUDY OF TELAPREVIR (TVR) WITH PEGINTERFERON ALFA-2A (P) AND RIBAVIRIN (R) IN SUBJECTS WITH WELL-DOCUMENTED PRIOR P/R NULL RESPONSE, NON-RESPONSE OR RELAPSE: PRELIMINARY RESULTS
48. 774 BASELINE AND ON-TREATMENT FACTORS ASSOCIATED WITH HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH AND WITHOUT CIRRHOSIS FOLLOWING TREATMENT WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN
49. 7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
50. 993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.